Yes, Rinvoq Treats Certain Arthritis Types
Rinvoq (upadacitinib) is an FDA-approved oral JAK inhibitor for adults with moderate to severe rheumatoid arthritis (RA) when methotrexate alone isn't enough or tolerated. It reduces joint pain, swelling, and damage by blocking inflammation pathways.[1]
Which Arthritis Conditions Does Rinvoq Cover?
Rinvoq also treats:
- Active psoriatic arthritis (PsA) in adults and kids 2+ who need TNF blockers or failed them.
- Active ankylosing spondylitis (AS), also called radiographic axial spondyloarthritis.
- Non-radiographic axial spondyloarthritis with inflammation on MRI.
It does not treat osteoarthritis (OA), the wear-and-tear type in knees or hips.[1][2]
How Does Rinvoq Compare to Other Arthritis Drugs?
| Drug | Type | Arthritis Targets | Administration |
|------|------|-------------------|---------------|
| Rinvoq (upadacitinib) | JAK inhibitor | RA, PsA, AS, nr-axSpA | Daily pill |
| Xeljanz (tofacitinib) | JAK inhibitor | RA, PsA, AS | Twice-daily pill |
| Humira (adalimumab) | TNF blocker | RA, PsA, AS, more | Injection every 1-2 weeks |
| Enbrel (etanercept) | TNF blocker | RA, PsA, AS | Weekly injection |
Rinvoq often works faster than biologics for RA symptom relief, but all carry infection risks from immune suppression.[1][3]
Common Side Effects and Patient Warnings
Upper respiratory infections, nausea, and elevated liver enzymes occur most often. Black box warnings cover serious infections, heart events, cancer, blood clots, and death—especially in older patients or smokers. Avoid live vaccines; monitor lipids and blood counts.[1][2]
Who Makes Rinvoq and When Do Patents Expire?
AbbVie manufactures Rinvoq, launched in 2019. Key U.S. patents expire around 2033, with challenges from generics like Sandoz. Exclusivity ends sooner for some uses.[4]
Sources
[1]: FDA Rinvoq Label
[2]: Rinvoq.com Prescribing Info
[3]: Arthritis Foundation Comparison
[4]: DrugPatentWatch Rinvoq Patents